Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors

NCT07259889 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors (Phase 1)

Interventions

DRUG: NK cell preparation

Sponsor

Guangzhou Xiling Biotechnology Co., Ltd.